Regulation of hepcidin expression by inflammation-induced activin B

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kanamori, Yohei ^a   Sugiyama, Makoto ^b   Hashimoto, Osamu ^b   Murakami, Masaru ^c   Matsui, Tohru ^a   Funaba, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c AZABU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR 2; ALK2 PROTEIN, RAT; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; HAMP PROTEIN, RAT; HEPCIDIN; LIPOPOLYSACCHARIDE; MYELOPID; SMAD PROTEIN;

ANIMAL; BIOSYNTHESIS; BOVINE; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; LIVER CELL; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TOXIC HEPATITIS;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CATTLE; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENE EXPRESSION REGULATION; HEPATOCYTES; HEPCIDINS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SMAD PROTEINS;

EID: 85002662446     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38702     Document Type: Article

References (64)

1. Pigeon, C. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276, 7811-7819 (2001).
2. Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093 (2004).
3. Sasu, B. J. et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammationinduced anemia. Blood 115, 3616-3624 (2010).
4. Hentze, M. W., Muckenthaler, M. U., Galy, B., Camaschella, C. Two to tango: regulation of mammalian iron metabolism. Cell 142, 24-38 (2010).
5. Meynard, D., Babitt, J. L., Lin, H. Y. The liver: conductor of systemic iron balance. Blood 123, 168-176 (2014).
6. Kautz, L. et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112, 1503-1509 (2008).
7. Andriopoulos, B. Jr. et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41, 482-487 (2009).
8. Truksa, J., Peng, H., Lee, P., Beutler, E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 103, 10289-10293 (2006).
9. Tanaka, T., Narazaki, M., Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6, a016295 (2014).
10. Ganz, T. Systemic iron homeostasis. Physiol Rev 93, 1721-1741 (2013).
11. Miyazono, K., Kamiya, Y., Morikawa, M. Bone morphogenetic protein receptors and signal transduction. J Biochem 147, 35-51 (2010).
12. Massagué, J. TGF signalling in context. Nat Rev Mol Cell Biol 13, 616-630 (2012).
13. Sakaki-Yumoto, M., Katsuno, Y., Derynck, R. TGF-family signaling in stem cells. Biochim Biophys Acta 1830, 2280-2296 (2013).
14. Lee, P., Peng, H., Gelbart, T., Beutler, E. The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA 101, 9263-9265 (2004).
15. Yu, P. B. et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 14, 1363-1369 (2008).
16. Steinbicker, A. U. et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 117, 4915-4923 (2011).
17. Theurl, I. et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118, 4977-4984 (2011).
18. Jones, K. L. et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 104, 16239-16244 (2007).
19. Besson-Fournier, C. et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 120, 431-439 (2012).
20. Wiater, E., Vale, W. Activins and inhibins in The TGF-family (Ed. Derynck, R., Miyazono, K.) 79-120 (Cold Spring Harbor Laboratory Press, 2008).
21. Canali, S. et al. Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice. Endocrinology 157, 1146-1162 (2016).
22. Ling, N. et al. Pituitary FSH is released by a heterodimer of the-subunits from the two forms of inhibin. Nature 321, 779-782 (1986).
23. Vale, W. et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321, 776-779 (1986).
24. Austyn, J. M., Gordon, S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11, 805-815 (1981).
25. Newman, P. J. The biology of PECAM-1. J Clin Invest 99, 3-8 (1997).
26. Baliga, B. S., Pronczuk, A. W., Munro, H. N. Mechanism of cycloheximide inhibition of protein synthesis in a cell-free system prepared from rat liver. J Biol Chem 244, 4480-4489 (1969).
27. Casanovas, G., Mleczko-Sanecka, K., Altamura, S., Hentze, M. W., Muckenthaler, M. U. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distalhepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med (Berl) 87, 471-480 (2009).
28. Truksa, J., Lee, P., Beutler, E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 113, 688-695 (2009).
29. Verga Falzacappa, M. V. et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109, 353-358 (2007).
30. Ling, N. et al. Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. Proc Natl Acad Sci USA 82, 7217-7221 (1985).
31. Nakamura, T. et al. Isolation and characterization of native activin B. J Biol Chem 267, 16385-16389 (1992).
32. Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17, 3091-3100 (1998).
33. Tsuchida, K. et al. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol 220, 59-65 (2004).
34. Bernard, D. J., Lee, K. B., Santos, M. M. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod Biol Endocrinol 4, 52 (2006).
35. Gressner, O. A., Gressner, A. M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 28, 1065-1079 (2008).
36. Gressner, O. A. et al. Intracrine signaling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. Liver Int 28, 1207-1216 (2008).
37. Gressner, O. A. et al. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor actions in hepatocytes-but without modulating bone morphogenetic protein 7 signaling. Hepatology 49, 2021-2030 (2009).
38. Tojo, M. et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-. Cancer Sci 96, 791-800 (2005).
39. Zhou, Y. et al. Receptor internalization-independent activation of Smad2 in activin signaling. Mol Endocrinol 18, 1818-1826 (2004).
40. Liu, Z. H. et al. Characterization of isoforms of activin receptor-interacting protein 2 that augment activin signaling. J Endocrinol 189, 409-421 (2006).
41. Murakami, M., Kawachi, H., Ogawa, K., Nishino, Y., Funaba, M. Receptor expression modulates the specificity of transforming growth factor-signaling pathways. Genes Cells 14, 469-482 (2009).
42. Aoki, H. et al. Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci 114, 1483-1489 (2001).
43. Furutani, Y., Umemoto, T., Murakami, M., Matsui, T., Funaba, M. Role of endogenous TGF-family in myogenic differentiation of C2C12 cells. J Cell Biochem 112, 614-624 (2011).
44. Miyazono, K., Miyazawa, K. Id: a target of BMP signaling. Sci STKE 2002, pe40 (2002).
45. Korchynskyi, O., ten Dijke, P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277, 4883-4891 (2002).
46. Bondestam, J. et al. cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). Cytogenet Cell Genet 95, 157-162 (2001).
47. Murakami, M. et al. Expression of activin receptor-like kinase 7 in adipose tissues. Biochem Genet 51, 202-210 (2013).
48. Daly, A. C., Randall, R. A., Hill, C. S. Transforming growth factor-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28, 6889-6902 (2008).
49. Liu, I. M. et al. TGF-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGF switch. EMBO J 28, 88-98 (2009).
50. Wrighton, K. H., Lin, X., Yu, P. B., Feng, X. H. Transforming growth factor can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem 284, 9755-9763 (2009).
51. Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF/ALK5 signaling. Mol Cell 12, 817-828 (2003).
52. Kanamori, Y., Murakami, M., Matsui, T., Funaba, M. Role of a TPA-responsive element in hepcidin transcription induced by the bone morphogenetic protein pathway. Biochem Biophys Res Commun 466, 162-166 (2015).
53. Sanvitale, C. E. et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 8, e62721 (2013).
54. Horbelt, D. et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem 290, 3390-3404 (2015).
55. Vogt, J., Traynor, R., Sapkota, G. P. The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell Signal 23, 1831-1842 (2011).
56. Willis, S. A., Zimmerman, C. M., Li, L., Mathews, L. S. Formation and activation by phosphorylation of activin receptor complexes. Mol Endocrinol 10, 367-379 (1996).
57. Schuppan, D., Gorrell, M. D., Klein, T., Mark, M., Afdhal, N. H. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 30, 795-808 (2010).
58. Hasegawa, Y., Eto, Y., Ibuki, Y., Sugino, H. Activin as autocrine and paracrine factor in the ovary. Horm Res 41 Suppl 1, 55-62 (1994).
59. Kaneko, H., Noguchi, J., Kikuchi, K., Todoroki, J., Hasegawa, Y. Alterations in peripheral concentrations of inhibin A in cattle studied using a time-resolved immunofluorometric assay: relationship with estradiol and follicle-stimulating hormone in various reproductive conditions. Biol Reprod 67, 38-45 (2002).
60. Kaneko, H., Noguchi, J., Kikuchi, K., Hasegawa, Y. Molecular weight forms of inhibin A and inhibin B in the bovine testis change with age. Biol Reprod 68, 1918-1925 (2003).
61. Kanamori, Y., Murakami, M., Matsui, T., Funaba, M. The regulation of hepcidin expression by serum treatment: requirements of the BMP response element and STAT-and AP-1-binding sites. Gene 551, 119-126 (2014).
62. Asano, H. et al. Diet-induced changes in Ucp1 expression in bovine adipose tissues. Gen Comp Endocrinol 184, 87-92 (2013).
63. Duran, E. M. et al. Presenilin-1 detection in brain neurons and FOXP3 in peripheral blood mononuclear cells: normalizer gene selection for real time reverse transcriptase PCR using the deltadeltaCt method. Front Biosci 10, 2955-2965 (2005).
64. Funaba, M., Murakami, M. A sensitive detection of phospho-Smad1/5/8 and Smad2 in Western blot analyses. J Biochem Biophys Methods 70, 816-819 (2008).